All In Biotech

Drug Trial Radar · NCT07951190

An Open-label Study to Evaluate the Long-Term Safety and Tolerability of Iptacopan in Patients With Complement Mediated Diseases.

An Open-label, Single-arm, Multicenter Roll-over Extension Program (REP) to Characterize the Long-term Safety and Tolerability of Iptacopan (LNP023) in Patients Who Have Completed a Clinical Trial (Parent Study) in the Iptacopan Pediatric Program

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

36

Planned (sponsor's estimate)

Start

Nov 16, 2026

Primary completion

Nov 25, 2032

Study completion Nov 25, 2032

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Nov 20, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 3 years, up to 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this single-arm, multicenter, Phase IIIb roll-over extension study is to assess the long-term safety, tolerability, and efficacy of iptacopan in participants with complement mediated diseases.

Conditions

  • Complement Mediated Diseases e.g. PNH, IgAN

Interventions

  • IptacopanDrug

    Participants \>12 years of age will receive iptacopan 200 mg twice daily, and participants aged 2 to \<12 years will receive weight-based dosing.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: From Day 1 through End of Treatment (EOT)/End of Study (EOS), up to approximately 3 years

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.